Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

NCT05908409 is registered in ClinicalTrials.gov with IDP Discovery Pharma S.L. as lead sponsor.

NCT NCT05908409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05908409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)
Lead sponsor
IDP Discovery Pharma S.L.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 5, 2023
Completion date
March 22, 2026
Enrollment
37 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll), diffuse large b-cell lymphoma, not otherwise specified, double hit lymphoma, high grade b-cell lymphoma, not otherwise specified, multiple myeloma (mm), triple hit lymphoma